Identifying CDKN3 Gene Expression as a Prognostic Biomarker in Lung Adenocarcinoma via Meta-Analysis

dc.contributor.authorZang, X.en_US
dc.contributor.authorChen, Minen_US
dc.contributor.authorZhou, Y.en_US
dc.contributor.authorXiao, G.en_US
dc.contributor.authorXie, Y.en_US
dc.contributor.authorWang, X.en_US
dc.date.accessioned2015-09-08T20:39:21Z
dc.date.available2015-09-08T20:39:21Z
dc.date.created2015-03-24en_US
dc.date.issued2015-03-24en_US
dc.descriptionIncludes supplementary materials.en_US
dc.description.abstractLung cancer is among the major causes of cancer deaths, and the survival rate of lung cancer patients is extremely low. Recent studies have demonstrated that the gene CDKN3 is related to neoplasia, but in the literature severe controversy exists over whether it is involved in cancer progression or, conversely, tumor inhibition. In this study, we investigated the expression of CDKN3 and its association with prognosis in lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC) using datasets in Lung Cancer Explorer (LCE; http://qbrc.swmed.edu/lce/). We found that CDKN3 was up-regulated in ADC and SCC compared to normal tissues. We also found that CDKN3 was expressed at a higher level in SCC than in ADC, which was further validated through meta-analysis (coefficient = 2.09, 95% CI = 1.50–2.67, P &lt; 0.0001). In addition, based on meta-analysis for the prognostic value of CDKN3, we found that higher CDKN3 expression was associated with poorer survival outcomes in ADC (HR = 1.65, 95% CI = 1.39–1.96, P < 0.0001), but not in SCC (HR = 1.10, 95% CI = 0.84–1.44, P = 0.494). Our findings indicate that CDKN3 may be a prognostic marker in ADC, though the detailed mechanism is yet to be revealed.en_US
dc.description.sponsorship"This work was supported by NIH grants 5R01CA152301 and 1R01CA172211 and by Cancer Prevention Research Institute of Texas award RP101251."en_US
dc.identifier.bibliographicCitationZang, X., M. Chen, Y. Zhou, G. Xiao, et al. 2015. "Identifying CDKN3 gene expression as a prognostic biomarker in lung adenocarcinoma via meta-analysis." Cancer Informatics 14(S2): 183-191 doi: 10.4137/CIN.S17287.en_US
dc.identifier.issn1176-9351en_US
dc.identifier.issueSupplement 2en_US
dc.identifier.urihttp://hdl.handle.net/10735.1/4600
dc.identifier.volume14en_US
dc.language.isoenen_US
dc.publisherLibertas Academica Ltd.en_US
dc.relation.urihttp://dx.doi.org/10.4137/CIN.S17287
dc.rightsCC BY-NC 3.0 (Attribution-NonCommercial)en_US
dc.rights©2015 The Authorsen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/en_US
dc.sourceCancer Informatics
dc.subjectCdkn3en_US
dc.subjectLung Neoplasmsen_US
dc.subjectAdenocarcinomaen_US
dc.subjectSquamous Cell Carcinomaen_US
dc.subjectMeta-Analysisen_US
dc.subjectBiological Tumor Markersen_US
dc.subjectPrognosisen_US
dc.subjectCDKN3en_US
dc.subjectGeneen_US
dc.subjectGene Expressionen_US
dc.subjectGene expression Regulationen_US
dc.subjectHumanen_US
dc.subjectSurvival Rateen_US
dc.titleIdentifying CDKN3 Gene Expression as a Prognostic Biomarker in Lung Adenocarcinoma via Meta-Analysisen_US
dc.type.genreArticleen_US

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
NSM-3634-272784.12.pdf
Size:
936.5 KB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
NSM-3634-272784.12.suppl.pdf
Size:
2.9 MB
Format:
Adobe Portable Document Format
Description:
Supplement

Collections